Dec 29, 2011 by Brian Orelli, PhDIs 2012 Make or Break for Cell Therapeutics?The biotech that wouldn't die.
Dec 29, 2011 by Brian Orelli, PhDWhat to Look For With Seattle Genetics in 2012The launch of its new drug Adcetris will be key.
Dec 28, 2011 by Brian Orelli, PhDBiotech Post-Holiday RegiftingSometimes it's better to not have received in the first place.
Dec 27, 2011 by Brian Orelli, PhDExelixis 2011: Not What the Doctor OrderedA tale of an inability to get a Special Protocol Assessment from the FDA.
Dec 27, 2011 by Brian Orelli, PhD2011 No Dreamboat for MannKindAn FDA rejection and a long wait is a bad combination.
Dec 23, 2011 by Brian Orelli, PhDThe Next Trend in Biotech PartnershipsBiosimilar development partnerships are popping up everywhere.
Dec 23, 2011 by Brian Orelli, PhDThe Biotech Garage Sale ContinuesExelixis and Sanofi end their drug-development pact.
Dec 23, 2011 by Brian Orelli, PhDGeron's Hurry-Up-and-Wait StrategyClinical trials started, now the waiting begins.
Dec 20, 2011 by Brian Orelli, PhDWhat's Up With the Back-Slapping, Sequenom?Some sales numbers would be nice.
Dec 20, 2011 by Brian Orelli, PhDIf You Can't Beat 'Em, Join 'Em: Amgen Goes GenericBiosimilars are coming -- might as well get a piece of the action.
Dec 16, 2011 by Brian Orelli, PhDDendreon 2011: Supply Constrained to Missed GuidanceA year in review for the biotech.
Dec 16, 2011 by Brian Orelli, PhDBiotech Royalties, Almost as Good as CashThey're flexible, and all royalties have value.
Dec 15, 2011 by Brian Orelli, PhDBioSante Shares Crushed by Placebo EffectBioSante's LibiGel efficacy is not deemed statistically significant.
